Literature DB >> 7742453

Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient.

P Tebas1, F Sultan, R J Wallace, V Fraser.   

Abstract

Mycobacterium chelonae (formerly known as M. chelonae subspecies chelonae) is a rapidly growing mycobacterium that can cause disseminated infections, especially in immunocompromised hosts. The bacterium is typically resistant to antimicrobial agents; less than 20% of M. chelonae isolates are susceptible to trimethoprim-sulfamethoxazole, doxycycline, erythromycin, or ciprofloxacin. Findings in a recent study suggested that clarithromycin may be the drug of choice for the treatment of cutaneous (disseminated) disease due to M. chelonae. We describe a 60-year-old heart transplant patient with disseminated M. chelonae infection for whom monotherapy with clarithromycin failed because of the rapid development of resistance to the drug.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7742453     DOI: 10.1093/clinids/20.2.443

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  20 in total

1.  Clarithromycin resistance to Mycobacterium abscessus.

Authors:  B A Brown-Elliott; R J Wallace
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

Review 2.  Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.

Authors:  Barbara A Brown-Elliott; Kevin A Nash; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

3.  Update on nontuberculous mycobacterial infections in solid organ and hematopoietic stem cell transplant recipients.

Authors:  B M Knoll
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

Review 4.  Endocarditis due to rare and fastidious bacteria.

Authors:  P Brouqui; D Raoult
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

5.  Activities of linezolid against rapidly growing mycobacteria.

Authors:  R J Wallace; B A Brown-Elliott; S C Ward; C J Crist; L B Mann; R W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

6.  Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  Erythema Induratum Caused by Mycobacterium chelonei in an Immunocompetent Patient.

Authors:  Shannon M Campbell; Richard R Winkelmann; Dawn L Sammons
Journal:  J Clin Aesthet Dermatol       Date:  2013-05

8.  Clinical and radiological features of pulmonary disease caused by rapidly growing mycobacteria in cancer patients.

Authors:  K Jacobson; R Garcia; H Libshitz; E Whimbey; K Rolston; D Abi-Said; I Raad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

Review 9.  Infections Caused by Rapidly Growing Mycobacteria spp in Children and Adolescents With Cancer.

Authors:  Nopporn Apiwattankul; Patricia M Flynn; Randall T Hayden; Elisabeth E Adderson
Journal:  J Pediatric Infect Dis Soc       Date:  2014-05-07       Impact factor: 3.164

Review 10.  Clinical and taxonomic status of pathogenic nonpigmented or late-pigmenting rapidly growing mycobacteria.

Authors:  Barbara A Brown-Elliott; Richard J Wallace
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.